Literature DB >> 29322474

Pharmacovigilance in developing countries (part II): a path forward.

Shaimaa Elshafie1,2, Anne Marie Roberti3, Iman Zaghloul4.   

Abstract

In recent years, attention to pharmacovigilance has gained momentum in developing countries, however awareness of, and policies or systems for pharmacovigilance in most developing countries still lags sharply behind developed countries. This article proposes different strategies to encourage the introduction and sustain the advancement of robust pharmacovigilance systems in developing countries. To this end, this article seeks to accomplish the ultimate goal of pharmacovigilance in a developing country context; ensuring patient safety and promoting safe and rational use of drugs.

Entities:  

Keywords:  Developing countries; Drug safety; Global initiatives; Monitoring; Pharmacovigilance; Regulatory actions; Reporting

Mesh:

Year:  2018        PMID: 29322474     DOI: 10.1007/s11096-017-0588-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  16 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Africa struggles to improve drug safety.

Authors:  Bernard Appiah
Journal:  CMAJ       Date:  2012-06-11       Impact factor: 8.262

3.  Pharmacovigilance in developing countries.

Authors:  Munir Pirmohamed; Kwame N Atuah; Alex N O Dodoo; Peter Winstanley
Journal:  BMJ       Date:  2007-09-08

Review 4.  Pharmacovigilance in resource-limited countries.

Authors:  Sten Olsson; Shanthi N Pal; Alex Dodoo
Journal:  Expert Rev Clin Pharmacol       Date:  2015-06-03       Impact factor: 5.045

5.  Mark Dybul, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Authors:  Charles Dearman
Journal:  BMJ       Date:  2016-06-27

6.  How to achieve international action on falsified and substandard medicines.

Authors:  Amir Attaran; Donna Barry; Shamnad Basheer; Roger Bate; David Benton; James Chauvin; Laurie Garrett; Ilona Kickbusch; Jillian Clare Kohler; Kamal Midha; Paul N Newton; Sania Nishtar; Paul Orhii; Martin McKee
Journal:  BMJ       Date:  2012-11-13

7.  Need for involving consumers in Nepal's pharmacovigilance system.

Authors:  Nisha Jha; Devendra Singh Rathore; P Ravi Shankar; Bhupendra Bahadur Thapa; Gajendra Bhuju; Mohammed Alshakka
Journal:  Australas Med J       Date:  2014-04-30

8.  Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.

Authors:  Sten Olsson; Shanthi N Pal; Andy Stergachis; Mary Couper
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

9.  Technologies for detecting falsified and substandard drugs in low and middle-income countries.

Authors:  Stephanie Kovacs; Stephen E Hawes; Stephen N Maley; Emily Mosites; Ling Wong; Andy Stergachis
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

10.  Strengthening medical product regulation in low- and middle-income countries.

Authors:  Charles Preston; Mary Lou Valdez; Katherine Bond
Journal:  PLoS Med       Date:  2012-10-23       Impact factor: 11.069

View more
  6 in total

1.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08

2.  Causality assessment of adverse drug reactions by applying a global introspection method in a high complexity hospital.

Authors:  Renata Rezende de Menezes; Maria das Dores Graciano Silva; Antônio Luiz Pinho Ribeiro; Marcelo Martins Pinto Filho; Gláucia Helena Martinho; Luna Elisabeth Carvalho Ferreira; Maria Auxiliadora Parreiras Martins
Journal:  Explor Res Clin Soc Pharm       Date:  2021-09-02

3.  Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.

Authors:  Jens-Ulrich Stegmann; Viviane Jusot; Olga Menang; Gregory Gardiner; Sabino Vesce; Stephanie Volpe; Anderson Ndalama; Felix Adou; Opokua Ofori-Anyinam; Olakunle Oladehin; Yolanda Guerra Mendoza
Journal:  BMC Public Health       Date:  2022-08-17       Impact factor: 4.135

4.  Spontaneous adverse drug reaction reporting by community pharmacists: preparedness and barriers.

Authors:  Mohamed Bahlol; Mary Bushell; Hani M J Khojah; Rebecca Susan Dewey
Journal:  Saudi Pharm J       Date:  2022-04-19       Impact factor: 4.562

Review 5.  A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.

Authors:  Hamza Y Garashi; Douglas T Steinke; Ellen I Schafheutle
Journal:  Ther Innov Regul Sci       Date:  2022-06-03       Impact factor: 1.337

6.  Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria.

Authors:  Rasaq Adisa; Tomilayo I Omitogun
Journal:  BMC Health Serv Res       Date:  2019-12-03       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.